EUVIMEDEUVIMED entdecken
Crossref

Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti–PD-1–Based Immunotherapy as Curative-Intent Treatment

Jie-Hai Yu, Le-En Liao, Bin-Yi Xiao, Xuan Zhang, Ai-Wen Wu, Yong Cheng, Jing-Hua Tang, Wu Jiang, Ling-Heng Kong, Kai Han, Wei-Jian Mei, Zhi-Gang Hong und 6 weitere

Journal of the National Comprehensive Cancer Network · 2024-04 · 22 (3)

DOI: 10.6004/jnccn.2023.7096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024-04. Verfasst von Jie-Hai Yu und 17 weiteren Autor:innen. Beteiligte Einrichtung: 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzho…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant anti–PD-1 therapy has shown encouraging efficacy in patients with deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer (LARC), which suggests its potential as a curative-intent therapy and a promising treatment option for organ preservation. We aimed to investigate the long-term outcomes of patients with dMMR/MSI-H LARC who experienced clinical complete response (cCR) after anti–PD-1 therapy.

Methods

We retrospectively analyzed patients with dMMR/MSI-H LARC who achieved cCR and received nonoperative management following neoadjuvant anti–PD-1–based treatment from 4 Chinese medical centers. Patients were followed up for at least 1 year after they achieved cCR, their clinical data were collected, and survival outcomes were analyzed using the Kaplan-Meier method.

Results

A total of 24 patients who achieved cCR and received nonoperative management from March 2018 to May 2022 were included, with a median age of 51.0 years (range, 19.0–77.0 years). The median treatment course to reach cCR was 6.0 (range, 1.0–12.0). Fifteen patients (62.5%) continued their treatments after experiencing cCR, and the median treatment course was 17.0 (range, 3.0–36.0). No local regrowth or distant metastasis was observed in a median follow-up time of 29.1 months (range, 12.6–48.5 months) after cCR. The 3-year disease-free and overall survivals were both 100%.

Conclusions

Patients with dMMR/MSI-H locally advanced or low-lying rectal cancer who achieved cCR following anti–PD-1–based therapy had promising long-term outcomes. A prospective clinical trial with a larger sample size is required to further validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsRectal NeoplasmsAdultAgedHumansMiddle AgedYoung AdultDNA Mismatch RepairImmunotherapyMicrosatellite InstabilityNeoadjuvant TherapyRetrospective StudiesTreatment Outcome

Autor:innen und Institutionen

  • 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • 2Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • 3Department of Colorectal Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
  • 4Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Gastrointestinal Cancer Center, Peking University Cancer Hospital and Institute, Beijing, Chin…
  • 5Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • 6Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.

Zitieren

APA

Yu, J. H., Liao, L. E., Xiao, B. Y., Zhang, X., Wu, A. W., Cheng, Y., Tang, J. H., Jiang, W., Kong, L. H., Han, K., Mei, W. J., Hong, Z. G., Yang, W. J., Li, D. D., Pan, Z. Z., Li, Y. F., Zhang, X. S., & Ding, P. R. (2024). Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti–PD-1–Based Immunotherapy as Curative-Intent Treatment. Journal of the National Comprehensive Cancer Network, 22(3). https://doi.org/10.6004/jnccn.2023.7096

Vancouver

Yu JH, Liao LE, Xiao BY, Zhang X, Wu AW, Cheng Y, et al. Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti–PD-1–Based Immunotherapy as Curative-Intent Treatment. Journal of the National Comprehensive Cancer Network. 2024;22(3). doi:10.6004/jnccn.2023.7096

BibTeX
@article{Yu2024,
  author = {Yu, Jie-Hai and Liao, Le-En and Xiao, Bin-Yi and Zhang, Xuan and Wu, Ai-Wen and Cheng, Yong and Tang, Jing-Hua and Jiang, Wu and Kong, Ling-Heng and Han, Kai and Mei, Wei-Jian and Hong, Zhi-Gang and Yang, Wan-Jun and Li, Dan-Dan and Pan, Zhi-Zhong and Li, Yun-Feng and Zhang, Xiao-Shi and Ding, Pei-Rong},
  title = {Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti–PD-1–Based Immunotherapy as Curative-Intent Treatment},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2024},
  volume = {22},
  number = {3},
  doi = {10.6004/jnccn.2023.7096}
}
Kostenlos starten →